Clinical Trial Update: A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs. [Phase 4]

View source ↗

Summary

Phase 4 study evaluating adding tocilizumab to DMARDs in patients with moderate to severe rheumatoid arthritis not adequately controlled by DMARDs; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2014-07-02